Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase EARLY_PHASE1 1

Status

Completed 20Active not recruiting 12Recruiting 10Unknown 6Withdrawn 4Terminated 4

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 2Metastatic HER2-positive Breast Cancer With Brain Metastasis 1HER2-positive Breast Cancer 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × Ado-Trastuzumab Emtansine × Clear all
NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

University of Rochester

Phase 2 Withdrawn
Breast

HER2-positive Breast Cancer

NCT04351230 2022-05-26

T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer

Academic and Community Cancer Research United

Phase 2 Withdrawn
Breast

Breast Neoplasms

NCT03203616 2018-11-29

KIARA

Jules Bordet Institute

Phase 2 Withdrawn
Breast

Metastatic HER2-positive Breast Cancer With Brain Metastasis

NCT02725541 2016-09-14

NATURE

The Methodist Hospital Research Institute

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡